GlassScriptPhysician profile
Aruna Kundi
NPI 1497764963
$6,680.98
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $780 · 2021: $1,595 · 2022: $1,757 · 2023: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,017.85 | 2021-2023 | |
| Novo Nordisk INC | $868.64 | 2019-2023 | Ozempic |
| Amgen INC. | $758.65 | 2019-2023 | Repatha |
| Otsuka America Pharmaceutical, INC. | $472.87 | 2021-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $318.30 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $300.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $281.75 | 2019-2022 | |
| Lilly USA, LLC | $252.35 | 2020-2023 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.69 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $199.07 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $144.49 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $116.94 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $103.90 | 2022 | |
| Radius Health, INC. | $103.12 | 2019-2023 | Tymlos |
| Paratek Pharmaceuticals, INC. | $99.80 | 2021-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Kundi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.